See more : PT Bhuwanatala Indah Permai Tbk (BIPP.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Braxia Scientific Corp. (BRAXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Braxia Scientific Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jinke Smart Services Group Co., Ltd. (9666.HK) Income Statement Analysis – Financial Results
- Schrödinger, Inc. (SDGR) Income Statement Analysis – Financial Results
- Acura Pharmaceuticals, Inc. (ACUR) Income Statement Analysis – Financial Results
- J.K. Cement Limited (JKCEMENT.NS) Income Statement Analysis – Financial Results
- Yung Chi Paint & Varnish Mfg.Co.,Ltd (1726.TW) Income Statement Analysis – Financial Results
Braxia Scientific Corp. (BRAXF)
About Braxia Scientific Corp.
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. In addition, the company owns and operates multidisciplinary clinics for the treatment of mental health disorders. Braxia Scientific Corp. is headquartered in Mississauga, Ontario.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 1.88M | 1.49M | 1.01M | 212.00 |
| Cost of Revenue | 1.71M | 4.77M | 3.90M | 9.16K |
| Gross Profit | 171.74K | -3.28M | -2.89M | -8.95K |
| Gross Profit Ratio | 9.12% | -220.66% | -286.70% | -4,219.81% |
| Research & Development | 98.35K | 192.58K | 1.98M | 50.00K |
| General & Administrative | 5.47M | 6.46M | 6.18M | 68.28K |
| Selling & Marketing | 152.44K | 253.00K | 1.85M | 7.65K |
| SG&A | 5.62M | 3.66M | 5.67M | 113.52K |
| Other Expenses | 1.93M | -24.40K | -129.02K | 0.00 |
| Operating Expenses | 7.65M | 3.88M | 7.78M | 163.52K |
| Cost & Expenses | 9.36M | 8.65M | 11.68M | 172.68K |
| Interest Income | 0.00 | 4.95K | 3.27K | 0.00 |
| Interest Expense | 17.84K | 4.95K | 2.04K | 0.00 |
| Depreciation & Amortization | 565.88K | 23.17K | 19.80K | 2.07K |
| EBITDA | -12.70M | -7.14M | -10.65M | -170.40K |
| EBITDA Ratio | -674.24% | -479.86% | -1,055.93% | -80,377.36% |
| Operating Income | -7.48M | -7.16M | -10.67M | -172.47K |
| Operating Income Ratio | -397.00% | -481.41% | -1,057.89% | -81,353.77% |
| Total Other Income/Expenses | -5.81M | -5.05M | -77.91M | -3.13M |
| Income Before Tax | -13.29M | -12.18M | -88.45M | -172.72K |
| Income Before Tax Ratio | -705.22% | -818.72% | -8,771.75% | -81,473.11% |
| Income Tax Expense | -145.88K | -45.27K | 376.31K | -1.00 |
| Net Income | -13.14M | -12.13M | -88.83M | -172.72K |
| Net Income Ratio | -697.48% | -815.93% | -8,809.07% | -81,473.11% |
| EPS | -0.06 | -0.07 | -0.56 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.56 | 0.00 |
| Weighted Avg Shares Out | 228.42M | 175.24M | 157.64M | 39.44M |
| Weighted Avg Shares Out (Dil) | 228.42M | 175.24M | 157.64M | 39.44M |
Braxia Scientific Announces Change in Directors and CEO
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company") announced that Jerry Habuda has resigned as a director effective November 12, 2024. Peter Rizakos was appointed on...
Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
Sale of Company's Assets Approved Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), is pleased to announce the voting results from its Annual General and Special...
Braxia Announces Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company") announced today that an annual general and special meeting (the "Meeting") of the common shareholders will be...
Braxia Scientific Announces Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - August 5, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FWB: 4960), ("Braxia Scientific", or the "Company"), today announced that the Ontario Securities Commission (the "OSC") issued a failure-to-file cease trade order (the "FFCTO")...
Braxia Scientific Provides Update on Application for Management Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - July 25, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), today announced further to its press release of July 15, 2024, that the Ontario Securities Commission (the...
Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), today announced that it has made an application to the Ontario Securities Commission to approve a management...
Braxia Scientific Reports Q3 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders,...
Braxia Scientific Reports Mandatory Conversion of Debentures
Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders,...
Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced...
Braxia Scientific Reports Q1 Fiscal 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - August 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and...
Source: https://incomestatements.info
Category: Stock Reports